MedTrace Logo

Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

NCT05484414 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-12-10

No results posted yet for this study

Summary

This is a two-part randomized, double-blind, placebo-controlled study.

Conditions

Interventions

DRUG

SRP-3D (diethylamide)

SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL

DRUG

Placebo

Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL

Sponsors & Collaborators

  • South Rampart Pharma, LLC

    lead INDUSTRY

Principal Investigators

  • Hernan A Bazan, MD · CEO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-16
Primary Completion
2025-12-31
Completion
2026-03-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05484414 on ClinicalTrials.gov